Metabolic Longevity · 5mg × 10 vials
In plain terms: SLU-PP-332 is a research compound - oral, fast-acting and well studied.
SLU-PP-332 is a small-molecule (not a peptide) synthetic pan-agonist of the three estrogen-related receptors: ERRα, ERRβ, and ERRγ. These are orphan nuclear receptors expressed heavily in mitochondria-rich tissues (skeletal muscle, heart, brown fat, liver) where they sit upstream of PGC-1α, the master regulator of mitochondrial biogenesis. When SLU-PP-332 stabilizes ERRα in its active conformation, the receptor transcribes the same gene program a body produces in response to endurance exercise: PGC-1α upregulation, increased mitochondrial density, induction of fatty acid oxidation enzymes (CPT1B, ACADM, HADHA), and electron transport chain subunit expression. The end result is the cell behaves as if it has been trained, even at rest. This is why the compound is labeled an "exercise mimetic": it doesn't replicate the cardiovascular work of training, but it does replicate the downstream metabolic adaptation. Developed in the Burris and Patti labs at Saint Louis University (hence the SLU prefix). All published efficacy is preclinical (mouse and cell culture). No human pharmacokinetic, efficacy, or safety data exists, and there is no active Phase 1 trial. Customers running it are doing so off mouse-to-human dose scaling and community self-report.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
First-time users almost always start lower than the 5 mg/day floor that some vendors quote. Reason: half-life is ~1.5 hr in mice, so plasma levels peak fast and clear fast at any given mg, and going hard out of the gate produces sleep disturbance + fatigue. Reconstitute 5 mg vial with 2 ml BAC = 2.5 mg/ml, so 1 mg = 0.4 ml = 40 IU on a U-100 syringe. Inject morning or pre-workout. Track resting HR, sleep, and perceived endurance at week 2 and week 4 to assess response.
This is the community working range where most endurance/fat-ox reports come from. Splitting the dose is what separates intermediate from beginner usage; running 2-5 mg as a single shot wastes most of the dose because plasma clears fast. Most users in this band report measurable endurance improvement (treadmill, bike, lift volume) by week 3, fat composition shifts visible around week 4-6. Stack with MOTS-c on this protocol is common.
Advanced protocols are typically stacked (MOTS-c, SS-31, or both) and run alongside a real training program, not as a substitute for it. The compound mimics the molecular adaptation of training, but real exercise still drives the largest gains; SLU-PP-332 amplifies what training is already producing. Watch for sleep disruption and slight HR elevation at top doses. If sleep degrades, pull PM dose forward or drop back to 5-7.5 mg/day. Do not run continuously without the 2-week off period; ERR receptor desensitization signal in preclinical data suggests cycling matters.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
](https://www.biorxiv.org/content/10.1101/2022.10.05.510974v1.full) - original SLU-PP-332 paper, 70% longer treadmill time in untrained mice
Read study ↗PubMedSynthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity, PMC11584170peer-reviewed publication, mitochondrial biogenesis and exercise capacity data
Read study ↗Physician commentaryRevolution Health & Wellness - SLU-PP-332: Endurance, Fat Oxidation, and Performanceclinic-side framing on mechanism and dosing for longevity-focused customers
Read study ↗Physician commentarySuperpower - SLU-PP-332: A Pan-ERR Agonist Research Tool Compoundlongevity-MD framing on the compound and its place in mito stacks
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Sleep changes: most-reported, can run either direction (some users sleep deeper, some get insomnia if dosed too late in the day). Resolves with PM dose pulled forward to early afternoon
Mild fatigue or "metabolic shift" feeling weeks 1-2: typically resolves by week 3, described as the body adjusting to higher fat oxidation
Mild HR elevation at higher doses (5-10+ mg/day): not symptomatic for most, similar pattern to what's reported with other metabolism-up compounds
Injection site reactions: occasional redness/lump, manageable with site rotation and slower injection
Hunger shifts: some users report increased appetite (mitochondrial demand goes up), others report decreased appetite, no consistent direction
Endurance improvement: most-cited positive effect, reported as easier breathing during cardio, longer time-to-exhaustion at week 2-4, gym work capacity up
Route: SubQ (community standard; parent compound has poor oral bioavailability, which is why the Burris lab developed the sibling SLU-PP-915 as an oral analog)
Injection site: abdomen or outer thigh, rotate sites
Storage: refrigerated, ~28 days after reconstitution
Notes: SLU-PP-332 is slightly harder to dissolve than most peptides. Add BAC slowly down the inside wall of the vial, swirl gently until clear, do not shake. If powder hasn't fully dissolved after 5 minutes of gentle swirling, let it sit refrigerated for 30 minutes and reswirl. Some lab protocols use DMSO as solvent (stronger), but for standard research bac water is fine. Half-life is short (~1.5 hr in mice), so daily community protocols typically split into 2-3 doses across the day, or run it pre-workout for the acute aerobic response signal.